Cystic Fibrosis
|2 min read
Enterprise Therapeutics Granted ‘Rare Pediatric Disease Designation’ in the US for Novel Cystic Fibrosis Investigational Therapy ETD001
ETD001 commenced Phase 2 clinical trials in July 2024, expected to complete in 2025
|5 min read
Organ-on-a-Chip Technology Could Revolutionize Cystic Fibrosis Treatment
Lung Airway Chip could transform cystic fibrosis research, potentially leading to better treatments and outcomes
|4 min read
"Sweat Sticker" Diagnoses Cystic Fibrosis on the Skin in Real Time
New wearable device changes color to detect early disease marker in newborns' sweat
|2 min read
Cystic Fibrosis Carriers Are at Increased Risk for Cystic Fibrosis-Related Conditions
More than 10 million Americans are CF carriers, suggesting the burden of illness from CF-related conditions could be substantial
|2 min read
New Approach Shows Promise for Treating Cystic Fibrosis
Common antifungal drug improves lungs' ability to fight infection
|2 min read
Novel Experimental Treatment for Chronic Lung Diseases
Symptoms associated with both diseases can be alleviated by inhibiting the activity of an enzyme found in the lungs
|3 min read
Correct Antibiotic Dosing Could Preserve Lung Microbial Diversity in Cystic Fibrosis
Understanding microbial diversity at baseline may help to improve clinical practice and patient outcomesPage 1 of 1
